The document outlines an exclusive GP-led secondary deal for Project Klein, expected to close in June 2018. The deal involves a mid-market buyout strategy in Europe/UK, focusing on business and healthcare services. Key investment data includes an invested capital of €60-100m, a discount to NAV of over 5%, and a gross multiple of 1.1x. The portfolio consists of four companies, including a UK premium distributor and a network of medical and cosmetics clinics. Glendower Capital aims to leverage its track record in complex transactions and long-standing relationships to deliver a bespoke solution.
documents/EFTA01394777.pdf
{}